Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 3, 2003, Pages 166-171

  Natif, Noam ^b   Sclarovsky Benjaminov, Fabiana ^b   Van Dijk, David Jonathan ^b   Sulkes, Jacklin ^b   Gafter, Uzi ^b   Boner, Geoffrey ^b   Erman, Arie ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; INSULIN; LOSARTAN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HORMONE BLOOD LEVEL; KIDNEY HYPERTROPHY; KIDNEY MASS; NONHUMAN; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; PUERPERIUM; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; URINARY EXCRETION;

EID: 0141990928     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00113-6     Document Type: Article

References (23)

1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34.
2. Leehey DJ, Singh AK, Alavi N, Singa R. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000;58(suppl 77):S93-8.
3. Skinner S. The renin-angiotensin system in fertility and normal human pregnancy. In: Robertson JIS, Nicolls MG, eds. The renin-angiotensin system. London, UK: Gower Medical Publishing; 1993:1-16.
4. Derkx FHM, Stuenk C, Schalekamp MPA, Visser W, Huisveld IH, Schalekamp MADH. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in woman taking oral contraceptives. J Clin Endocrinol Metab 1986;63:1008-15.
5. August P, Sealy JE. The renin-angiotensin system in normal and hypertensive pregnancy. In: Laragh JH, Brenner BM, eds. Hypertension pathology, diagnosis and management. New York, NY: Raven Press, 1990:1761-78.
6. Reece EA, Coustan ER, Hayslett JP. Diabetic nephiopathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988;159:56-66.
7. van Dijk DJ, Boner G, Erman A. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. J Renin-Angiotensin-Aldosterone System 2002;2:193-8.
8. Hod M, van Dijk DJ, Karp M, Weintroub N, Rabinerson D, Bar Y, et al. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 1995;10:2328-33.
9. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.
10. Brenner BM, Cooper ME, de Zeeuv D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type II diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Erman A, van Dijk DJ, Chen-Gal B, David I, Giler S, Rosenfeld JB, et al. Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur J Clin Invest 1993;23:615-20.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing of protein-dye binding. Anal Biochem 1976;72:248-54.
13. Rabkin R, Shecter P, Dong Shi J, Boner G. Protein turnover in the hypertrophying kidney. Min Electrolyte Metab 1996;22: 153-6.
14. Defendini R, Zimmerman EA, Weare JA, Alhenc-Glas F, Erdos EA. Angiotensin-converting enzyme in epithelial and neuroepithelial cells. Neuroendocrinology 1983;37:32-40.
15. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos E, Largo G, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in normotensive rat model of the immune complex nephritis. Kidney Int 1995;48: 1778-91.
16. Weinstein T, Skutelsky E, Chagnac A, Hirsh Y, Gafter U. Enalapril modifies glycosaminoglycan expression in the glomerular basement membrane of rats with puromycin nephrosis. J Am Soc Nephrol 1999;10:F576.
17. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002;39[part2]:316-22.
18. Goetz RM, Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Cli Sci 1999;97:165-74.
19. Roccatello D, Mengozzi G, Gigliola G, Rossi D, Mosso R, Cacace G, et al. Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy. Nephrol Dial Transplant 2000; 15:988-93.
20. Spence SG, Allen HL, Cukierski MA, Manson GM, Robertson RT, Eydelloth RS. Defining the susceptible period of developmental toxicity for the AT-1 selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367-82.
21. Spence SG, Allen HL, Cukierski MA, Manson GM, Robertson RT. Eydelloth RS. Evaluation of the reproductive and developmental toxicity of the AT-1 selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:384-97.
22. Saji H, Yamanaka M, Hagieara A, Ijira R. Losartan and fetal toxic effects. Lancet 2001;357:363.
23. Chung NA, Lip YH, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1620-1.